FUJIFILM Aktie

 

India showcased its semiconductor ambitions at Semicon India 2025 with the unveiling of its first homegrown chip and a flurry of local partnerships. While global players such as ASML, Tokyo Electron, and Fujifilm expressed support, their moves remain exploratory, underscoring India's challenge in securing concrete foreign investment....

COLLEGE STATION, Texas--(BUSINESS WIRE)--FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization for biologics, vaccines, and advanced therapies, is pleased to announce the appointment of Samuel Hernandez, Ph.D., as senior vice president and site head for its College Station, Texas facility, effective Monday, August 25. With over two decades of biotechnology and pharmaceutical leadership experience, Dr. Hernandez is poised to lead the Texas site's approximately 770-strong team to achieve continued growth of cell culture and advanced therapies offerings. The previous site head, Keita Hirabayashi, has been appointed to the position of senior director, Corporate Office and board member of the Texas site. Dr. Hernandez joins FUJIFILM Biotechnologies from Amgen, where he recently served as executive director and head of Global Manufacturing Strategies and Technologies. In this role, he contributed to the strategy for manufacturing capacity expansion and integrated cutting...

Fujifilm Electronic Materials is considering a significant investment in India as part of its strategy to expand in the fast-growing semiconductor sector, according to a report by the Times of India....

Fujifilm Electronic Materials is considering establishing a factory in India, encouraged by the nation's growing semiconductor ecosystem and skilled workforce. The company is exploring various investment options, including direct production, licensed production with Indian firms, and joint ventures with semiconductor manufacturers. Fujifilm recognizes India's potential as both a talent hub and a significant market for semiconductor demand across diverse industries....

WASHINGTON (dpa-AFX) - Fujifilm Biotechnologies is preparing to open the first phase of its massive biologics manufacturing campus in Holly Springs, North Carolina, a site designed to rank among t......

-- Reached Alignment with the U.S. Food and Drug Administration (FDA) on Information Needed for Resubmission of the Biologics License Application (BLA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) -- -- Plan to Resubmit the BLA in December with FUJIFILM Biotechnologies (Fujifilm) as the Drug Substance Manufacturer and Will Request Priority Review -- -- Anticipate Submitting the MOLBREEVI Marketing Authorization Applications for Autoimmune PAP to the European Medicines Agency (EMA) and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in 1Q 2026 -- -- Reported ~$146M in Cash and Short-Term Investments as of June 30, 2025, Company Believes It Is Sufficiently Capitalized into 1Q 2027 --LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second quarter ending June 30, 2025 and provided a business update. “Fo...

Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...

FUJIY posts modest Q1 revenue growth on strength in Bio CDMO and Imaging, despite FX losses hitting net income....

Fujifilm Holdings posted an operating profit of JPY75.2 billion (approx. US$510 million) for the April–June 2025 quarter, a 21% year-over-year increase and the second straight quarterly record. The gains were driven by strong demand in semiconductor materials and digital imaging products....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

TOKYO (dpa-AFX) - FUJIFILM Holdings Corporation (FUJIF.PK, FUJIY.PK) on Wednesday registered a decline in net profit for the third quarter, mainly due to higher income tax expenses. However, the c......

Many of the company's camera bodies are now $200 more expensive than they were on Thursday evening....

Fujifilm Holdings Corp. raised US prices for the majority of its digital cameras and lenses on Friday, in some cases by hundreds of dollars, as President Donald Trump's tariffs continue to reverberate across the consumer tech industry....

TOKYO--(BUSINESS WIRE)--FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that the company has appointed Brian O'Donnelly as its Corporate Vice President, strengthening global leadership to drive growth in the Electronic Materials Business. He will continue serving as the President and CEO of FUJIFILM Electronic Materials USA, Inc., Senior Deputy General Manager of the Electronic Materials Business Division, FUJIFILM Corporation and Global Vice President of FUJIFILM Electronic Materials. Born and educated in Scotland, O'Donnelly has spent the majority of his 40-year career working in the Chemical and Semiconductor Materials industries, joining Fujifilm group in 2004. In 2014, he was appointed President and CEO of FUJIFILM Electronic Materials USA, where he has led significant growth of the business and its contributions to Fujifilm through new product development, customer and product portfolio expansions, and mergers and acquisitions. “Brian is a strong l...

Hunderte Druckermodelle von Brother, Fujifilm, Konica Minolta, Ricoh und Toshiba sind angreifbar. Angreifer nutzen die Sicherheitslücken nun aus. (Sicherheitslücke, Drucker)...

Fujifilm announced its plan to strengthen its business in materials for semiconductor back-end processes at a semiconductor materials business briefing held in Tokyo on July 15, 2025. The company aims to capture market share driven by rapidly expanding demand for AI servers, which will boost the semiconductor back-end process materials market....

Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...

NextCell Pharma AB (“NextCell” or “the Company”) is pleased to announce that its strategic collaboration with FUJIFILM Biosciences has been highlighted in an article published on 8 July by Genetic Engineering & Biotechnology News (GEN). The article covers FUJIFILM's recent rebranding and long-term ambition to act as a full-spectrum partner to drug and vaccine developers throughout the entire development cycle. The article, published by GEN – one of the top-ranked biotechnology industry publications, with a global readership of over 870,000 – recognises NextCell as part of FUJIFILM's...

NextCell Pharma AB's ("NextCell" or "the Company") has entered into a strategic collaboration with FUJIFILM Biosciences Inc. to bring together their core competences in mesenchymal stromal cells (MSCs) and raw materials for the life science sector. The aim of the collaboration is to provide researchers and developers in the cell therapy field with an integrated offering – standardised MSC products, optimised culture media, and cryopreservation solutions. As part of the rebranding of Fujifilm Irvine Scientific to FUJIFILM Biosciences, we are re-publishing the press release originally issued...

Die GFX100RF ist die erste Mittelformat-Kompaktkamera von Fujifilm. Sie steht agiles Fotografieren und hohe Bildqualität. Wir haben die Kamera getestet....